Related Experiment Videos
[Suicide gene therapy for prostate cancer--update of current development]
1Department of Urology, Okayama University Graduate School of Medicine and Dentistry.
Abstract:
Prostate cancer is the leading internal malignancy in men with an age over 50. Therapeutic options for patients with recurrence after hormonal therapy are limited. New therapeutic options are needed. In our previous studies, we demonstrated the efficacy and safety of 'suicide gene therapy' using herpes simplex virus-thymidine kinase gene transduction and ganciclovir therapy in an orthotopic mouse model. These preclinical studies resulted in the initiation of clinical trials using this approach in USA and Japan. Safety and positive clinical response were shown in these clinical studies. In this review article, current status of prostate cancer 'suicide' gene therapy is updated and future direction of its development is also discussed.
Insights
Prostate cancer gene therapy offers new hope for patients with recurrent disease. Suicide gene therapy using herpes simplex virus-thymidine kinase and ganciclovir shows promise in preclinical and clinical studies.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Context:
- Prostate cancer is a leading malignancy in men over 50.
- Limited therapeutic options exist for patients with recurrence after hormonal therapy.
- Novel treatment strategies are urgently needed.
Purpose:
- To review the current status of prostate cancer suicide gene therapy.
- To discuss the future directions for this therapeutic approach.
Summary:
- Suicide gene therapy, utilizing herpes simplex virus-thymidine kinase gene transduction and ganciclovir, has demonstrated efficacy and safety in preclinical orthotopic mouse models.
- Preclinical success led to clinical trials in the USA and Japan, showing positive clinical responses and safety.
- This review updates the current understanding and future prospects of prostate cancer suicide gene therapy.
Impact:
- Provides a comprehensive overview of a promising novel therapy for prostate cancer.
- Highlights the successful translation of preclinical findings into clinical trials.
- Informs future research and development in gene therapy for prostate cancer treatment.